|James O'Dell, M.D.|
The best treatment for the best price.
All patients want that, but when rheumatologists have a choice between two effective "gold standard" treatments, one costing 15 times more than the other, why is the expensive option most often selected?
UNMC's James O'Dell, M.D., and rheumatologists from around the world want to know which medication can provide the best care at the most economical price.
Dr. O'Dell, professor of internal medicine and chief of the rheumatology and immunology section, began pondering this question more than a decade ago.
It's a question the pharmaceutical companies didn't necessarily want answered, so they have not funded any studies to address the issue. But the answer could save tens of millions of dollars every year for patients and the government.
Dr. O'Dell initially turned to the manufacturers for answers, but pharmaceutical companies have little incentive to compare their products to less expensive therapies. Additionally, the Food and Drug Administration has never required these comparisons.
Frustrated, he designed a first-of-its-kind comprehensive $15 million study that will enroll 600 patients from 35 clinics and medical centers in the United States and Canada. The study, funded by Veterans Affairs (VA) and the Canadian Institute of Health Research, began in July 2007 and is expected to take nearly three years to complete.
Most rheumatoid arthritis studies have an 80 percent concentration of women, but because many patients will be enrolled through the VA, the study will have equal numbers of men and women.
The study, which took four years to develop, is called RACAT (pronounced rocket), an acronym for "Rheumatoid Arthritis: Comparison of Active Therapies."
- Using a combination of methotrexate, hydroxychloroquine and sulfasalazine, which costs patients approximately $1,000 a year as the first treatment option, to
- Using a combination of methotrexate and etanercept, which costs patients approximately $15,000 a year as the first option.
Participants in the study will take one combination of drugs for 24 weeks. If, after that time, there is not significant improvement, they will be switched to the other combination for 24 weeks.
Taking the study a step further, Dr. O'Dell also will determine what role genetics play in the different treatments, or who responds better to which drug combination.
"We'll look for genetic factors and biomarkers that predict disease progression and success or toxicity of the different strategies," Dr. O'Dell said. "Early treatment is the key to successfully managing this disease. Our hope is that one day doctors will be able to prescribe the most effective treatment for their patients based on genetics. That will eliminate a lot of experimenting."
More than 660 million people in the world, including 2 million in the United States, suffer from rheumatoid arthritis. The autoimmune disease causes chronic inflammation of the joints and other areas of the body, and affects people of all ages. Researchers have not been able to determine a cause or a cure for the disease, but treatments are available, with a goal of remission or near remission.
Methotrexate alone is an excellent, economical first-line therapy for a significant percentage of rheumatoid arthritis patients, Dr. O'Dell said. However, combination therapy is recommended for those patients who continue to have disease flares, which can result in permanent joint destruction and markedly shortened survivals.
In a 1996 New England Journal of Medicine study, Dr. O'Dell proved that triple therapy, a combination of three drugs -- methotrexate, sulfasalazine and hydroxychloroquine -- was 50 percent more effective in treating rheumatoid arthritis than methotrexate alone or the combination of sulfasalazine and hydroxychloroquine.
That study was conducted through the Rheumatoid Arthritis Investigational Network (RAIN), a group of rheumatologists and nurse-study coordinators in several states across the country. Dr. O'Dell founded RAIN in 1989; its home base is at UNMC.
The group established a serum, plasma, urine and blood bank for investigational purposes. Dr. O'Dell's original observations of genetic predictors were the first of their kind and have altered the way patients are treated. The current study brings together an impressive coalition of public and private health centers across two countries. In addition to the 10 sites in the RAIN network, Dr. O'Dell recruited 15 Veterans Affairs Medical Centers and 10 Canadian Rheumatology Research Consortium (CRRC) sites.
One of those sites, the San Francisco VA Medical Center, is slated to enroll 20 patients, said David Daikh, M.D., Ph.D., chief of rheumatology at the VA center, and associate professor of medicine at the University of California-San Francisco.
"This is an exciting, groundbreaking study that will answer important questions about the effective and economical treatments for patients with rheumatoid arthritis," he said. "As we gain more understanding about the disease and more therapies are developed, we can begin to turn our attention to the next big frontier of targeting therapeutics. That's where the genetic data will be helpful."
The VA and CRRC now spend more than $70 million every year on these expensive therapies and are very interested in the results of this study, Dr. O'Dell said.
"I think clinicians around the world will use this information to make better judgments for their patients who have rheumatoid arthritis," he said.